Literature DB >> 19513523

Apogossypolone inhibits cell growth by inducing cell cycle arrest in U937 cells.

Jian Sun1, Zhi-Ming Li, Zhe-Yu Hu, Zhao-Lei Zeng, Da-Jun Yang, Wen-Qi Jiang.   

Abstract

We examined the effect of apogossypolone (ApoG2), a new derivative from gossypol on cell cycle regulation in U937 human leukemic monocyte lymphoma cells in vitro. ApoG2 decreased the viability of U937 cells by inducing G1 arrest followed by apoptosis in a dose-dependent manner. The G0/G1 phase of the cell cycle is regulated by cyclin-dependent kinases (Cdk), cyclins and cyclin-dependent kinase inhibitors (Cdki). We show by western blot analysis, that the ApoG2-induced G1 arrest was mediated through the increased expression of Cdki proteins (p21cip1/waf1) with a simultaneous decrease in cdk2, cdk4, cyclin D1 and cyclin E expression. The induction of apoptosis after treatment with ApoG2 for 12, 24 and 48 h was demonstrated by flow cytometry analysis. ApoG2 also induced cytochrome c release and activation of caspase-3. To our knowledge, this is the first time that ApoG2 has been reported to potently inhibit the proliferation of human monocytic lymphoma U937 cells through G1 arrest. These findings suggest that ApoG2 may be a potential chemotherapeutic agent for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513523     DOI: 10.3892/or_00000424

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  10 in total

1.  Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.

Authors:  Jun Wei; Shinichi Kitada; John L Stebbins; William Placzek; Dayong Zhai; Bainan Wu; Michele F Rega; Ziming Zhang; Jason Cellitti; Li Yang; Russell Dahl; John C Reed; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2010-10-29       Impact factor: 7.446

Review 2.  Emerging Bcl-2 inhibitors for the treatment of cancer.

Authors:  Asfar S Azmi; Zhiwei Wang; Philip A Philip; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Expert Opin Emerg Drugs       Date:  2010-09-03       Impact factor: 4.191

3.  Pharmacologic inhibition of lactate production prevents myofibroblast differentiation.

Authors:  Robert Matthew Kottmann; Emma Trawick; Jennifer L Judge; Lindsay A Wahl; Amali P Epa; Kristina M Owens; Thomas H Thatcher; Richard P Phipps; Patricia J Sime
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-09-25       Impact factor: 5.464

Review 4.  Targeting the Bcl-2 family for cancer therapy.

Authors:  Shibu Thomas; Bridget A Quinn; Swadesh K Das; Rupesh Dash; Luni Emdad; Santanu Dasgupta; Xiang-Yang Wang; Paul Dent; John C Reed; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Ther Targets       Date:  2012-11-22       Impact factor: 6.902

5.  Apogossypolone (ApoG2) induces ROS-dependent apoptosis and reduces invasiveness of PC12 cells in vitro and in vivo.

Authors:  Dengqiang Lin; Xiaoxia Li; Lieyu Xu; Jianpo Lian; Yunze Xu; Li Meng; Xin Xie; Xiaojing Wang; Hongchao He; Danfeng Xu; Chenghe Wang; Yu Zhu
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

6.  Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapy.

Authors:  Ashiq Masood; Asfar S Azmi; Ramzi M Mohammad
Journal:  Cancers (Basel)       Date:  2011-06-01       Impact factor: 6.639

7.  An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic bcl-2 family proteins.

Authors:  Jun Wei; John L Stebbins; Shinichi Kitada; Rupesh Dash; Dayong Zhai; William J Placzek; Bainan Wu; Michele F Rega; Ziming Zhang; Elisa Barile; Li Yang; Russell Dahl; Paul B Fisher; John C Reed; Maurizio Pellecchia
Journal:  Front Oncol       Date:  2011-09-30       Impact factor: 6.244

8.  Apogossypolone targets mitochondria and light enhances its anticancer activity by stimulating generation of singlet oxygen and reactive oxygen species.

Authors:  Zhe-Yu Hu; Jing Wang; Gang Cheng; Xiao-Feng Zhu; Peng Huang; Dajun Yang; Yi-Xin Zeng
Journal:  Chin J Cancer       Date:  2011-01

Review 9.  Targeting Cell Survival Proteins for Cancer Cell Death.

Authors:  Manoj K Pandey; Sahdeo Prasad; Amit Kumar Tyagi; Lokesh Deb; Jiamin Huang; Deepkamal N Karelia; Shantu G Amin; Bharat B Aggarwal
Journal:  Pharmaceuticals (Basel)       Date:  2016-02-25

10.  New Bioactive Fused Triazolothiadiazoles as Bcl-2-Targeted Anticancer Agents.

Authors:  Rania Hamdy; Arwyn T Jones; Mohamed El-Sadek; Alshaimaa M Hamoda; Sarra B Shakartalla; Zainab M Al Shareef; Sameh S M Soliman; Andrew D Westwell
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.